IZEA Worldwide (IZEA) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Greetings, and welcome to the IZEA Worldwide First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Matt Gray, Vice President of Marketing. Please go ahead. Speaker1 Good afternoon, everyone, and welcome to IZEA's earnings call cov ...

Surgepays (SURG) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 note this conference is being recorded. I will now turn the conference over to your host, Mike McCormack, Managing Director of Investor Relations at Surg Pace. You may begin. Speaker1 Thank you, operator, and good afternoon, everyone. Welcome to the Surg Pays twenty twenty five First Quarter Financial Results Conference Call. Today's date is 05/13/2025. And on the call today from the company are Brian Cox, President and CEO and Tony Ev ...

GEN Restaurant Group (GENK) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Please also note today's event is being recorded. At this time, I would like to turn the floor over to Tom Kearl, the company's Chief Financial Officer. Sir, you may begin. Speaker1 Thank you, operator, and good afternoon. By now, everyone should have access to our first quarter twenty twenty five earnings release. If not, it can be found at www.jenkoreanbbq.com in the Investor Relations section. Before we begin our formal r ...

Financial Data and Key Metrics Changes - As of March 31, 2025, the company had $335.5 million in cash, cash equivalents, and investments [29] - Research and development expenses for Q1 2025 were $50.2 million, including $5 million in non-cash stock-based compensation [29] - General and administrative expenses for Q1 2025 were $15 million, including $7.1 million in non-cash stock-based compensation [29] - The net loss for Q1 2025 was $59.7 million, or $0.28 per share, including $12.2 million in non-cash stock-based compensation [29] - Updated guidance for 2025 indicates an expected cash burn of approximately $150 million, with full-year GAAP operating expenses projected at approximately $230 million [29] Business Line Data and Key Metrics Changes - The ALPHA-three trial has seen over 250 patients consented for MRD screening, with nearly half in the last three months, indicating improved site engagement [9][20] - ALLO-three sixteen is showing signs of efficacy in heavily pretreated advanced renal cell carcinoma, with a 50% best overall response rate in patients expressing high levels of CD70 [24] - ALLO-three 29 is set to launch the RESOLUTION trial mid-2025, aiming to change treatment for autoimmune diseases by potentially eliminating lymphodepletion [11][25] Market Data and Key Metrics Changes - Nearly 50 activated US sites are involved in the ALPHA-three trial, with plans for international expansion starting in Canada [21] - The company is experiencing strong enthusiasm from investigators, which is translating into increased patient screening activity [20][21] Company Strategy and Development Direction - The company is focused on making CAR T therapies more accessible through an allogeneic approach, with a strategy launched in January 2024 aimed at redefining cell therapy [6][13] - The company is prioritizing cash runway preservation, extending it into the second half of 2027, while driving forward with promising clinical trials [12][28] - The company is adapting its operational strategy to address macroeconomic challenges and enhance trial execution [12][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the evolving regulatory landscape and expresses confidence in the FDA's commitment to scientific integrity and patient-centered outcomes [14][15] - The company believes that strong science and meaningful clinical benefits will continue to prevail in the regulatory environment [16] - Management is optimistic about the potential of their allogeneic CAR T programs to reshape treatment paradigms in hematologic malignancies and solid tumors [27] Other Important Information - The company is making targeted reductions in manufacturing operations to achieve cost savings while maintaining core capabilities [28] - The ALLO-three sixteen data will be presented at ASCO on June 1, which is expected to be significant for the field [22] Q&A Session Summary Question: Progress of enrollment in the first line study and logistical issues - Management explained that site-related issues caused a 3-4 month delay in patient screening, but recent improvements in site engagement are translating into increased screening activity [35][36] Question: Differences in site-related factors between community and academic sites - Management indicated that there is no significant difference in the occurrence of site-related factors between community and academic sites, with both showing encouraging activity once operational [40][46] Question: Regulatory implications of expanding to international sites - Management stated that the global standard for frontline DLBCL treatment remains consistent, and the expansion is not expected to introduce significant heterogeneity [65] Question: Potential partnership for autoimmune programs - Management expressed willingness to partner on autoimmune programs to de-risk them, especially given the current market environment [68] Question: Expected data size for ALLO-three 29 - Management indicated that the expected data size for the initial readout will be limited due to the nature of the dose escalation study, but they are focused on ensuring robust data collection [75] Question: Overlap of site-related challenges in ex-US sites - Management believes that ex-US sites will be better equipped due to the integrated care model typically found in those regions [96]

CVD Equipment (CVV) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Greetings and thank you for standing by and welcome to the CVD Equipment Corporation's First Quarter twenty twenty five Earnings Call. As a reminder, this conference is being recorded. We will begin with some prepared remarks followed by a question and answer session. Presenting on the call today will be Emmanuel Lakios, President and CEO and member of the CVD Board of Directors and Richard Catalano, Executive Vice President and Chi ...

Urgent.ly (ULY) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good afternoon, and welcome to Urgently's First Quarter twenty twenty five Conference Call. As a reminder, today's call is being recorded and your participation implies consent to such recording. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. With that, I would like to turn the call over to Ms. Jenny Mitchell, Vice President of Finance Strategy and Inves ...

Kopin (KOPN) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good day, everyone, and welcome to the Kopin Corporation's First Quarter twenty twenty five Earnings Call. Please note that this event is being recorded. At this time, I'd like to turn the conference over to Brian Prineveau, Investor Relations for Kopen. Please go ahead. Speaker1 Thank you, and good afternoon, everyone. Before we get started, I'd like to remind everyone that during today's call, taking place on 05/13/2025, we will be makin ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was approximately $300,000, compared to $160,000 in the same period last year, representing an increase of 87.5% [16] - Operating expenses for Q1 were $4,700,000, up from $3,300,000 a year ago and down from $4,900,000 in the previous quarter [16] - Net loss for the quarter was $4,300,000, compared to a net loss of $3,100,000 for the same period last year [16] - Adjusted EBITDA loss was $3,900,000 for Q1, compared to a loss of $2,400,000 for the same period last year [18] - Remaining performance obligation (RPO) was $13,850,000, a decrease of $410,000 from the prior quarter but an increase from $4,030,000 a year ago [17] Business Line Data and Key Metrics Changes - The company is focusing on large enterprise deals and partnerships, with significant progress reported in contract negotiations with Fortune 500 companies [8][10] - A paid live production trial agreement was signed with a global Fortune 100 retailer, indicating a move towards long-term contracts [10] - The company is also in the final stages of contract negotiations with a major identity fraud platform [10] Market Data and Key Metrics Changes - The company reported generating $13,000,000 in new pipeline in Q1, with expectations to build on this in Q2 [46] - The demand for biometric solutions is increasing, particularly due to rising concerns over cyber attacks and fraud [6][7] Company Strategy and Development Direction - The company aims to become a leader in the biometric authentication market, focusing on speed, accuracy, privacy, and interoperability [12][13] - Strategic investments have been made in privacy key technology, allowing biometric authentication without storing biometric data [12] - The company is expanding into public sector opportunities and smart city projects in South America and India [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the $18,000,000 bookings target for 2025, despite delays in the sales process [19][16] - The macroeconomic environment is seen as dynamic, with potential for increased demand for biometric solutions due to rising fraud [6][7] Other Important Information - The company completed two capital raises in April and May, securing nearly $9,000,000 to improve its balance sheet and broaden its investor base [15] - The company received recognition as the best ID management platform in 2025 by FinTech Breakthrough Awards [14] Q&A Session Summary Question: When will the company start seeing leverage from partnerships? - Management indicated that they are already benefiting from partnerships and expect bookings to follow as they invest in channel partners [25][26] Question: Why are expenses high compared to revenue? - Management explained that current expenses are driven by investments in headcount for sales and R&D, which are necessary for future growth [29][30] Question: How many Fortune 500 clients are needed to meet the $18,000,000 goal? - Management stated that signing four to five large deals could potentially meet the target, with some deals large enough to cover the entire amount [36][37][40]

KinderCare Learning Companies (KLC) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 It is now my pleasure to introduce Olivia Keer, KinderCare's VP of Investor Relations. Ms. Keer, you may begin your conference. Speaker1 Thank you, and good evening, everyone. Welcome to KinderCare's first quarter earnings call. Joining me from the company are our Chief Executive Officer, Paul Thompson and Chief Financial Officer, Tony Amandy. Following Paul and Tony's comments today, we will have a question and answ ...

Financial Data and Key Metrics Changes - Research and development revenue for Q1 2025 rose 6% to $6,700,000 from $6,300,000 in Q1 2024, reflecting increased activity under the BARDA Project BioShield contract [12] - Gross margin increased to 47.2% from 46.6% in Q1 2024 due to a higher concentration of direct labor as a component of revenue [12] - General and administrative expenses decreased significantly from $5,100,000 in Q1 2024 to $4,100,000 in Q1 2025, primarily due to a focus on the BARDA contract and cost-cutting measures [12] - Operating loss for Q1 2025 was $896,000 compared to a net loss of $2,100,000 in Q1 2024 [13] - The company reported net income of $2,900,000 in Q1 2025, a significant improvement from a net loss of $3,200,000 in the same quarter last year [13] - Cash and cash equivalents totaled $14,100,000 as of March 31, 2025, up from $5,200,000 on December 31, 2024 [14] Business Line Data and Key Metrics Changes - The company is focused on advancing its DeepView technology and preparing for FDA submission, which is a key milestone for its product line [5][6] - The DeepView Snapshot M handheld device is in development, with two prototypes successfully assembled [9] Market Data and Key Metrics Changes - The company reiterated its revenue guidance for 2025 at approximately $21,500,000, which does not include contributions from sales of the DeepView system in the UK or Australia [14] Company Strategy and Development Direction - The company is transitioning from a research-focused organization to a commercial entity with a well-defined business focus for 2025 and beyond [4] - The primary goal is to achieve FDA de novo classification submission by the end of Q2 2025, which is critical for future growth [5] - The company is also developing its healthcare intellectual property subsidiary, Spectral IP, which is in the SEC registration process for an initial public offering [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the revenue guidance and noted that the first quarter's strong performance reflects efforts to focus on the FDA submission [18][19] - The company has had over 10 pre-submission meetings with the FDA, which have been constructive and supportive [22][23] - Management is optimistic about the prospects for growth and development, emphasizing the importance of the BARDA partnership [40][41] Other Important Information - The company completed a debt financing agreement of up to $15,000,000, with an initial drawdown of $8,500,000, and raised approximately $2,700,000 in equity financing [7][8] - The burn validation study results, which utilized over 340 billion clinically validated data points, demonstrated the effectiveness of the DeepView technology [6] Q&A Session Summary Question: Guidance on revenue expectations - Management indicated that the revenue guidance of $21,500,000 seems reasonable, although they may restate it if performance continues to exceed expectations [18][19] Question: Preparation for FDA submission - Management highlighted a strong relationship with BARDA and noted that they have been working closely with the FDA to de-risk the submission process [22][23] Question: General administrative expenses outlook - Management anticipates general and administrative expenses to remain consistent with Q1 results, focusing on operational efficiencies [32][33] Question: Development of Snapshot M device - Management confirmed that while they are focused on the FDA submission, they are also advancing the development of the Snapshot M device for military use [38][41] Question: Future relationships with the DoD - Management acknowledged the importance of developing relationships with the DoD and emphasized ongoing efforts to improve the Snapshot M device [49][50]